Recent Developments at Pharma Companies: Special Research on Aerie Pharmaceuticals, AEterna Zentaris, Affimed, Agenus, and Agile Therapeutics
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, February 3, 2015 /PRNewswire/ --
Moments ago, Analysts Review released new research updates concerning several important developing situations including Aerie Pharmaceuticals (NASDAQ: AERI), AEterna Zentaris (NASDAQ: AEZS), Affimed (NASDAQ: AFMD), Agenus (NASDAQ: AGEN), and Agile Therapeutics (NASDAQ: AGRX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
AERI Research Report: ( http://get.analystsreview.com/pdf/?c=Aerie%20Pharmaceuticals&d=03-Feb-2015&s=AERI ),
AEZS Research Report: ( http://get.analystsreview.com/pdf/?c=AEterna%20Zentaris&d=03-Feb-2015&s=AEZS ),
AFMD Research Report: ( http://get.analystsreview.com/pdf/?c=Affimed&d=03-Feb-2015&s=AFMD ),
AGEN Research Report: ( http://get.analystsreview.com/pdf/?c=Agenus&d=03-Feb-2015&s=AGEN ),
AGRX Research Report: ( http://get.analystsreview.com/pdf/?c=Agile%20Therapeutics&d=03-Feb-2015&s=AGRX ).
============
--
Analyst Update: Clinical Trials and Study Updates, Publications,and Leadership Changes
Reviewed by: Rohit Tuli, CFA®
The U.S. stocks ended higher on Monday helped by a late-session rally in the energy shares which also offset a fresh set of disappointing economic data. The Dow Jones Industrial Average rose 1.14% to close at 17,361.04, the S&P 500 increased 1.30% to close at 2,020.85, and the Nasdaq Composite gained 0.89% to end at 4,676.69. Energy shares led the advance, with the S&P 500 energy sector ending up nearly 3% following rise in the crude oil prices. Disappointing data on consumer spending and the manufacturing sector released on Monday weighed on the market early in the session. The European stocks ended on a mixed note on Monday amid continued uncertainty over Greece's debt negotiations and rising worries over the health of global economies. The pan-European Euro Stoxx 600 Index closed largely flat. In Asia, markets were mostly under pressure after fresh data raised concerns over China's manufacturing sector.
Aerie Pharmaceuticals, Inc. (Aerie Pharmaceuticals) announced the acceleration of the expected timeline for reporting efficacy results from the Company's 400-patient Phase 3 registration trial ("Rocket 1") of RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
AEterna Zentaris Inc. (AEterna Zentaris) announced that the final data for Phase 1 portion of ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer was published in Clinical Cancer Research's December issue.
Affimed N.V. (Affimed) has appointed Dr. Martin Treder as its Chief Scientific Officer. Dr. Treder will lead Affimed's ongoing efforts to further develop and utilize its proprietary biand trispecific TandAb platforms for the expansion of its internal pipeline and will provide scientific support for its clinical programs and for collaborations with corporate partners.
Agenus Inc. (Agenus) has announced that its partner GlaxoSmithKline's ZOE-50 Phase 3 study has met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo.
Agile Therapeutics, Inc. (Agile Therapeutics) gave an update on its Phase 3 SECURE Study, a single-arm, open-label, multicenter Phase 3 trial that will assess the efficacy, safety and tolerability of the Company's investigational once-weekly transdermal contraceptive patch, Twirla (AG200-15).
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article